{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:07:59Z","timestamp":1770437279770,"version":"3.49.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.bcp.2014.01.023","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T04:31:11Z","timestamp":1390537871000},"page":"158-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo"],"prefix":"10.1016","volume":"88","author":[{"given":"Nataly","family":"Tarasenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don R.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gili","family":"Berkovitch-Luria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elinor","family":"Bardugo-Nissim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Weitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Rephaeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2014.01.023_bib0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","article-title":"HDAC expression and clinical prognosis in human malignancies","volume":"280","author":"Weichert","year":"2009","journal-title":"Cancer Letters"},{"key":"10.1016\/j.bcp.2014.01.023_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.bcp.2014.01.023_bib0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt's lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2014.01.023_bib0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10585-007-9131-5","article-title":"Histone deacetylases: target enzymes for cancer therapy","volume":"25","author":"Mottet","year":"2008","journal-title":"Clinical and Experimental Metastasis"},{"key":"10.1016\/j.bcp.2014.01.023_bib0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/35077256","article-title":"Cancer epidemiology in the last century and the next decade","volume":"411","author":"Peto","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.01.023_bib0030","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-08-2048","article-title":"Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes","volume":"15","author":"Hauswald","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0035","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-08-2787","article-title":"Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications","volume":"15","author":"Schrump","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.bcp.2014.01.023_bib0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2009.03.013","article-title":"Histone deacetylase inhibitors as anti-neoplastic agents","volume":"280","author":"Batty","year":"2009","journal-title":"Cancer Letters"},{"key":"10.1016\/j.bcp.2014.01.023_bib0050","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1021\/mp200329f","article-title":"Histone deacetylase inhibitors: emerging mechanisms of resistance","volume":"8","author":"Robey","year":"2011","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.bcp.2014.01.023_bib0055","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"Prince","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0060","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/jm049428p","article-title":"The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters","volume":"48","author":"Nudelman","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2014.01.023_bib0065","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ijc.2910560625","article-title":"Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line","volume":"56","author":"Aviram","year":"1994","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.bcp.2014.01.023_bib0070","first-page":"2142","article-title":"A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies","volume":"8","author":"Patnaik","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.lungcan.2004.03.002","article-title":"Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer","volume":"45","author":"Reid","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2014.01.023_bib0080","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/1535-7163.MCT-05-0087","article-title":"Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas","volume":"4","author":"Entin-Meer","year":"2005","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bcp.2014.01.023_bib0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1215\/15228517-2006-032","article-title":"In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas","volume":"9","author":"Entin-Meer","year":"2007","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bcp.2014.01.023_bib0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10637-006-6213-1","article-title":"The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs","volume":"24","author":"Rephaeli","year":"2006","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.bcp.2014.01.023_bib0095","doi-asserted-by":"crossref","first-page":"e31393","DOI":"10.1371\/journal.pone.0031393","article-title":"Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor","volume":"7","author":"Tarasenko","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2014.01.023_bib0100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10637-010-9542-z","article-title":"The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity","volume":"30","author":"Tarasenko","year":"2012","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.bcp.2014.01.023_bib0105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10585-008-9179-x","article-title":"Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)","volume":"25","author":"Tarasenko","year":"2008","journal-title":"Clinical and Experimental Metastasis"},{"key":"10.1016\/j.bcp.2014.01.023_bib0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15216540500079093","article-title":"The power and potential of doxorubicin-DNA adducts","volume":"57","author":"Cutts","year":"2005","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bcp.2014.01.023_bib0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.redox.2013.01.014","article-title":"Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms","volume":"1","author":"Kalyanaraman","year":"2013","journal-title":"Redox Biology"},{"key":"10.1016\/j.bcp.2014.01.023_bib0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.bcp.2014.01.023_bib0125","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.bjc.6603781","article-title":"Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity","volume":"96","author":"Rephaeli","year":"2007","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.bcp.2014.01.023_bib0130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial","volume":"97","author":"Atmaca","year":"2007","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.bcp.2014.01.023_bib0135","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2014.01.023_bib0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/1535-7163.MCT-08-1076","article-title":"Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo","volume":"8","author":"Kortenhorst","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bcp.2014.01.023_bib0145","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2014.01.023_bib0150","series-title":"Novel N-acylated, O-acylated and (bis or tris)-N,O-acylated derivatives of purinic and pyrimidinic nucleoside analogs","author":"Nudelman, A. Rephaeli","year":"2009"},{"key":"10.1016\/j.bcp.2014.01.023_bib0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0223-5234(00)01199-5","article-title":"Prodrugs of butyric acid: novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases","volume":"36","author":"Nudelman","year":"2001","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bcp.2014.01.023_bib0160","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.bcp.2014.01.023_bib0165","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ijc.21030","article-title":"In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer","volume":"116","author":"Rephaeli","year":"2005","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.bcp.2014.01.023_bib0170","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.bcp.2014.01.023_bib0175","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00432-006-0116-6","article-title":"Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7\/Dx cell lines","volume":"132","author":"Engel","year":"2006","journal-title":"Journal of Cancer Research and Clinical"},{"key":"10.1016\/j.bcp.2014.01.023_bib0180","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou\u2013Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0185","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1161\/CIRCULATIONAHA.109.905471","article-title":"Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart","volume":"121","author":"Wang","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2014.01.023_bib0190","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1476-4598-9-200","article-title":"Transcriptome analysis of human cancer reveals a functional role of heme oxygenase-1 in tumor cell adhesion","volume":"9","author":"Tauber","year":"2010","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.bcp.2014.01.023_bib0195","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1097-2765(04)00102-9","article-title":"Endostatin's antiangiogenic signaling network","volume":"13","author":"Abdollahi","year":"2004","journal-title":"Molecular Cell"},{"key":"10.1016\/j.bcp.2014.01.023_bib0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/cvr\/cvt011","article-title":"FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters","volume":"98","author":"Wang","year":"2013","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gde.2009.11.001","article-title":"The ups and downs of Myc biology","volume":"20","author":"Soucek","year":"2010","journal-title":"Current Opinion in Genetics & Development"},{"key":"10.1016\/j.bcp.2014.01.023_bib0210","doi-asserted-by":"crossref","first-page":"34725","DOI":"10.1074\/jbc.R600017200","article-title":"The ins and outs of MYC regulation by posttranslational mechanisms","volume":"281","author":"Vervoorts","year":"2006","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bcp.2014.01.023_bib0215","first-page":"8194","article-title":"Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9)","volume":"61","author":"Cutts","year":"2001","journal-title":"Cancer Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0220","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1054\/bjoc.2000.1459","article-title":"High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours","volume":"83","author":"Koukourakis","year":"2000","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.bcp.2014.01.023_bib0225","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H","article-title":"Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin","volume":"92","author":"Fabel","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2014.01.023_bib0230","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI39675","article-title":"EMT: when epithelial cells decide to become mesenchymal-like cells","volume":"119","author":"Kalluri","year":"2009","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.bcp.2014.01.023_bib0235","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2014.01.023_bib0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-011-9281-4","article-title":"Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy","volume":"30","author":"Tartour","year":"2011","journal-title":"Cancer Metastasis Reviews"},{"key":"10.1016\/j.bcp.2014.01.023_bib0245","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/cvr\/cvp062","article-title":"Cardioprotective growth factors","volume":"83","author":"Hausenloy","year":"2009","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2012.09.007","article-title":"Carbon monoxide: Mechanisms of action and potential clinical implications","volume":"137","author":"Rochette","year":"2013","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.bcp.2014.01.023_bib0255","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1423-0127-17-80","article-title":"Over-expression of HO-1 on mesenchymal stem cells promotes angiogenesis and improves myocardial function in infarcted myocardium","volume":"17","author":"Zeng","year":"2010","journal-title":"Journal of Biomedical Science"},{"key":"10.1016\/j.bcp.2014.01.023_bib0260","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2014.01.023_bib0265","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0090-3019(98)00028-7","article-title":"c-Myc oncogene family expression in glioblastoma and survival","volume":"51","author":"Herms","year":"1999","journal-title":"Surgical Meurology"},{"key":"10.1016\/j.bcp.2014.01.023_bib0270","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1158\/0008-5472.CAN-11-3891","article-title":"MAX and MYC: a heritable breakup","volume":"72","author":"Cascon","year":"2012","journal-title":"Cancer Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0275","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/0008-5472.CAN-10-3776","article-title":"MYC and metastasis","volume":"71","author":"Wolfer","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.bcp.2014.01.023_bib0280","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.yjmcc.2010.10.026","article-title":"iPS cells: a source of cardiac regeneration","volume":"50","author":"Yoshida","year":"2011","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.bcp.2014.01.023_bib0285","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrn3060","article-title":"The neurobiology of gliomas: from cell biology to the development of therapeutic approaches","volume":"12","author":"Westphal","year":"2011","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.bcp.2014.01.023_bib0290","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fonc.2013.00261","article-title":"Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy","volume":"3","author":"Jakopovic","year":"2013","journal-title":"Frontiers in Oncology"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:57:31Z","timestamp":1757768251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295214000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0006295214000471"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2014.01.023","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2014.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}